C07K 16/2818
Against cd28 or cd152
Official title: {against CD28 or CD152}
C07K16/2818 (Against cd28 or cd152) appears on 2,807 US grants and 6,852 published applications in this corpus.
Search patents in C07K- Granted patents
- 2,807
- Published applications
- 6,852
- Assignees
- 2,090
- Inventors
- 12,374
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 5 | 0 |
| 1999 | 17 | 0 |
| 2000 | 6 | 0 |
| 2001 | 4 | 2 |
| 2002 | 5 | 18 |
| 2003 | 4 | 21 |
| 2004 | 10 | 29 |
| 2005 | 9 | 30 |
| 2006 | 13 | 30 |
| 2007 | 10 | 21 |
| 2008 | 7 | 19 |
| 2009 | 18 | 41 |
| 2010 | 17 | 29 |
| 2011 | 19 | 44 |
| 2012 | 23 | 36 |
| 2013 | 23 | 41 |
| 2014 | 24 | 50 |
| 2015 | 37 | 75 |
| 2016 | 32 | 146 |
| 2017 | 51 | 227 |
| 2018 | 92 | 340 |
| 2019 | 171 | 589 |
| 2020 | 280 | 674 |
| 2021 | 338 | 812 |
| 2022 | 353 | 809 |
| 2023 | 316 | 790 |
| 2024 | 344 | 774 |
| 2025 | 362 | 663 |
| 2026 | 211 | 542 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Canine PD-L1 antibody, antigen binding fragments thereof, and methods of use thereof6 Oct 2026US 12,753,234 B2Purdue Research Foundation
- Anti-CCR8 antibodies for treating cancer29 Sep 2026US 12,747,296 B2Bristol-Myers Squibb Company
- PD-1 agonist and method of using same22 Sep 2026US 12,742,010 B2First Tracks Biotherapeutics, Inc.
- Piperidine urea derivatives for cancer therapy15 Sep 2026US 12,734,164 B2NeuroPn Therapeutics, Inc.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab8 Oct 2026US 2026/0306649 A1Agensys, Inc.
- Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives8 Oct 2026US 2026/0306652 A1Merck Sharp & Dohme Corp.
- Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an il-2 mutant and a cd80 extracellular domain8 Oct 2026US 2026/0308251 A1Gi Innovation, Inc.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Antibodies to human programmed death receptor PD-1454US 8,354,509 B2MSD Oss B.V. · 2013
- Antibodies against PD-1450US 7,488,802 B2MedImmune, LLC · 2009